Vaxcyte (PCVX) Valuation Check As VAX A1 Begins Phase 1 Group A Strep Trial

Simply Wall St.06-08 09:21

Vaxcyte (PCVX) has dosed the first participant in its Phase 1 trial of VAX-A1, a Group A Strep vaccine candidate. This is a key early step in testing a product aimed at a large unmet medical need. See...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641177964?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-06-08 09:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641177964","market":"hk","top_or_hot":-1,"title":"Vaxcyte (PCVX) Valuation Check As VAX A1 Begins Phase 1 Group A Strep Trial","media":"Simply Wall St.","content":"<div>\n<p>Vaxcyte (PCVX) has dosed the first participant in its Phase 1 trial of VAX-A1, a Group A Strep vaccine candidate. This is a key early step in testing a product aimed at a large unmet medical need. See...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-valuation-check-as-vax-a1-begins-phase-1-group\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxcyte (PCVX) Valuation Check As VAX A1 Begins Phase 1 Group A Strep Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxcyte (PCVX) Valuation Check As VAX A1 Begins Phase 1 Group A Strep Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-08 09:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-valuation-check-as-vax-a1-begins-phase-1-group><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaxcyte (PCVX) has dosed the first participant in its Phase 1 trial of VAX-A1, a Group A Strep vaccine candidate. This is a key early step in testing a product aimed at a large unmet medical need. See...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-valuation-check-as-vax-a1-begins-phase-1-group\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0009354923.USD","symbol_name":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-valuation-check-as-vax-a1-begins-phase-1-group","article_id":"2641177964","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-valuation-check-as-vax-a1-begins-phase-1-group","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2641177964","pubTimestamp":1780881700,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Vaxcyte (PCVX) has dosed the first participant in its Phase 1 trial of VAX-A1, a Group A Strep vaccine candidate. This is a key early step in testing a product aimed at a large unmet medical need.\nSee our latest analysis for Vaxcyte.\nDespite the positive development for VAX-A1, recent share price momentum has been soft, with the stock down 10.66% on a 30 day share price return and 20.16% on a 90 day share price return, while the 1 year total shareholder return of 28.03% and 5 year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","PCVX":"Vaxcyte, Inc.","BK4139":"生物科技","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)"},"translate_title":"随着VAX A1开始1期A组链球菌试验，Vaxcyte(PCVX)进行估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PCVX":1.5},"content_text":"Vaxcyte (PCVX) has dosed the first participant in its Phase 1 trial of VAX-A1, a Group A Strep vaccine candidate. This is a key early step in testing a product aimed at a large unmet medical need. See our latest analysis for Vaxcyte. Despite the positive development for VAX-A1, recent share price momentum has been soft, with the stock down 10.66% on a 30 day share price return and 20.16% on a 90 day share price return, while the 1 year total shareholder return of 28.03% and 5 year total shareholder return of 115.17% indicate a much stronger long term picture. If Vaxcyte’s pipeline has caught your eye, this could be a good moment to broaden your search and check out 39 healthcare AI stocks With Vaxcyte still in the loss-making, pre-revenue stage yet trading at a multi billion US$ valuation, the question for you is simple: is this pipeline being undervalued, or is the market already pricing in years of future growth? AdvertisementMost Popular Narrative: 56.6% Undervalued Vaxcyte last closed at $47.36, while the most followed narrative anchors on a fair value of $109 based on long term vaccine opportunities and funding runway.  Expanded adult pneumococcal vaccination recommendations in the US and increasing adoption of adult PCV programs internationally are enlarging the addressable market for higher valency vaccines such as VAX-31. This directly relates to potential future revenue scale.  Read the complete narrative. Want to understand why this narrative assigns such a high value to a company with no current revenue and ongoing losses? The core assumptions revolve around steep revenue ramp up, a sharp swing toward industry style margins, and a valuation multiple that leans heavily on those projected earnings. Curious how those ingredients combine to support a fair value more than double the last close? Result: Fair Value of $109 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this depends on complex late stage trials and large scale manufacturing going to plan, and on future vaccine guidelines not favoring rival products instead. Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page. Next Steps With sentiment in this article leaning positive but still balanced, now is a good time to check the data yourself and decide where you stand, including weighing 2 key rewards and 2 important warning signs Looking for more investment ideas? If you stop with just one stock today, you might miss other opportunities that better fit your goals, risk comfort, and time horizon.  Target value first and see which companies currently screen as 49 high quality undervalued stocks for potentially more compelling price tags. Prioritise resilience by reviewing 61 resilient stocks with low risk scores, so your watchlist is not built only on higher volatility stories. Get ahead of the crowd by scanning the screener containing 21 high quality undiscovered gems before they sit on everyone else's radar.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641177964","isCrawlerRequest":true}